9 reports of this reaction
2.9% of all ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE reports
#2 most reported adverse reaction
DIZZINESS is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Walgreens. There are 9 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE to DIZZINESS. This represents approximately 2.9% of all 310 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 9 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.9% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience dizziness while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.